Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ahead Of The Mix: Symphogen Leads The Way To Antibody Combinations

This article was originally published in Start Up

Executive Summary

The concept of multiple antibodies in one mixture to treat disease, once solely the provenance of serum-derived polyclonal therapies, is enticing a new wave of developers. With a technological head start and a vault full of private backing, Danish firm Symphogen is the field’s pioneer – and hopes to avoid the arrows.

You may also be interested in...



Amgen Gobbles Up Micromet In $1.16 Billion BiTE

With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).

AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092425

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel